An integrated analysis aiming at identifying novel predictive biomarkers of VEN efficacy and suitable combinatorial regimens identified the ex vivo resistance of myelomonocytic/monocytic AML (French-American-British (FAB) classification M4/M5 or CD14+ phenotype) blasts against VEN [2]. This evidence concerns the gene CD14 and acute myeloid leukemia.